🇺🇸 FDA

Intelligence · Clinical Pipeline

R&D Pipeline Programs

ClinicalTrials.gov programs linked to pharma sponsors — phase, modality, and trial IDs for BD and competitive intelligence.

Programs indexed
20,548
Companies
1,769
Drugs tracked
4,797

Quick answer

NovaPharmaNews tracks 20,548 pharmaceutical R&D pipeline programs sourced from ClinicalTrials.gov, linked to sponsor companies. Each profile includes development phase, modality, trial status, NCT identifiers, and indication text — searchable for business development and competitive intelligence.

850 results for “Elan” Clear

  1. Glasdegib

    Jazz Pharmaceuticals Ireland Limited

    Acute Myelogenous Leukemia (AML) Due to Therapy

    phase 2 small molecule active

    1 trial

  2. HZN-1116, HZN-1116, commercially available 0.9% (w/v) saline solution intended for SC administration, HZN-1116

    Elan Pharma International

    Sjögren’s Syndrome

    phase 2 small molecule active

    1 trial

  3. Hyperimmune plasma

    Lxo Ireland Designated Activity Company

    SARS-CoV 2

    phase 2 mab completed

    1 trial

  4. IBRANCE 125 mg hard capsules, IBRANCE 125 mg hard capsules, IBRANCE 125 mg hard capsules, Faslodex 250 mg solution for injection., JZP598

    Jazz Pharmaceuticals Ireland Limited

    Breast cancer patients including those with locally advanced (unresectable) or metastatic HER2-positive, HR-positive breast cancer

    phase 2 small molecule active

    1 trial

  5. IMC-M113V

    Immunocore Ireland Limited

    Chronic HIV infection

    phase 2 small molecule active

    1 trial

  6. IMC-R117C

    Immunocore Ireland Limited

    Cancer

    phase 2 small molecule active

    1 trial

  7. IMD-1041

    Lxo Ireland Designated Activity Company

    Chronic Obstructive Pulmonary Disease

    phase 2 small molecule active

    1 trial

  8. IMFINZI 50 mg/mL concentrate for solution for infusion., Ceralasertib, Inflectra 100 mg powder for concentrate for solution for infusion, Mycophenolate Mofetil 250 mg Capsules

    AstraZeneca AB

    Unresectable or Advanced Melanoma

    phase 2 small molecule active

    1 trial

  9. INEBILIZUMAB

    Elan Pharma International

    Neuromyelitis optica spectrum disorder (NMOSD; also known as Devic's syndrome and previously known as neuromyelitis optica [NMO])

    phase 2 small molecule active

    1 trial

  10. INXN-2001

    Alaunos Therapeutics

    Melanoma

    phase 2 mab completed

    1 trial

  11. IO102-IO103

    IO Biotech

    Melanoma

    phase 2 small molecule active

    2 trials

  12. IOV-3001

    Iovance Biotherapeutics B.V.

    Unresectable Melanoma

    phase 2 mab active

    1 trial

  13. IOV-4001

    Iovance Biotherapeutics B.V.

    Unresectable Melanoma

    phase 2 mab active

    1 trial

  14. Ifinatamab deruxtecan

    Daiichi Sankyo

    Recurrent or Metastatic Solid Tumors (endometrial cancer (EC); head and neck squamous cell carcinoma (HNSCC); pancreatic ductal adenocarcinoma (PDAC); colorectal cancer (CRC); hepatocellular carcinoma (HCC); adenocarcinoma of esophagus, gastroesophageal junction, and stomach (Ad-Eso/GEJ/gastric); urothelial carcinoma (UC); ovarian cancer (OVC); cervical cancer (CC); biliary tract cancer (BTC); human epidermal growth factor 2 (HER2)-low breast cancer (BC); HER2 immunohistochemistry (IHC) 0 BC; and cutaneous melanoma)

    phase 2 small molecule active

    1 trial

  15. Infusion of MSC

    Lxo Ireland Designated Activity Company

    Discordant Immunological Response in HIV Infected Subjects

    phase 2 small molecule completed

    1 trial

  16. Infusion of autologous mononuclear bone marrow cells

    Lxo Ireland Designated Activity Company

    Idiopathic Dilated Cardiomyopathy

    phase 2 small molecule terminated

    1 trial

  17. Infusion of mesenchymal stem cells from adipose tissue

    Lxo Ireland Designated Activity Company

    Faecal Incontinence

    phase 2 small molecule completed

    1 trial

  18. Injectable suspension of allogeneic adult mesenchymal stem cells

    Lxo Ireland Designated Activity Company

    Hidradenitis Suppurativa

    phase 2 mab active

    1 trial

  19. Intismeran autogene

    Merck KGaA, Darmstadt, Germany

    Malignant Melanoma

    phase 2 mab active

    1 trial

  20. Intraarterial infusion of autologous bone marrow cells

    Lxo Ireland Designated Activity Company

    Critical Limb Ischemia (CLI)

    phase 2 other completed

    2 trials

  21. Intracoronary infusion of autologous bone marrow cells

    Lxo Ireland Designated Activity Company

    Dilated Cardiomyopathy

    phase 2 other completed

    1 trial

  22. Intravenous administration of 1 million of MSC

    Lxo Ireland Designated Activity Company

    Amyotrophic Lateral Sclerosis

    phase 2 small molecule completed

    1 trial

  23. Isturisa 1 mg film-coated tablets, Isturisa 5 mg film-coated tablets, Isturisa 10 mg film-coated tablets

    Recordati Ireland

    Cushing's disease

    phase 2 small molecule active

    1 trial

  24. JMT108

    Shanghai University of Traditional Chinese Medicine

    Unresectable Locally Advanced or Metastatic Melanoma

    phase 2 small molecule active

    1 trial

Frequently asked questions

What is the NovaPharmaNews pipeline directory?

It is a searchable index of 20,548 clinical development programs grouped by sponsor company, with phase (Phase 1–3), modality, trial status, and linked NCT IDs from ClinicalTrials.gov.

Where does pipeline data come from?

Program records are derived from ClinicalTrials.gov and linked to NovaPharmaNews company profiles. Trial status and phase reflect registry data at last sync — verify on ClinicalTrials.gov before investment or partnering decisions. See our data sources page for attribution.

How do I find pipeline programs by company or phase?

Use the search box to match program name, indication, company name, or slug. Results are ordered with late-stage (Phase 3) programs first. Open any row to view the full program profile under its sponsor company.

Data attribution and licensing: Data sources